Fast track designation signals an attempt to address high unmet need in platinum-resistant ovarian cancer and may enable more frequent FDA engagement and rolling review pathways contingent on ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) ...
Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the first ...
PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that on March 28, 2024, the Company ...
Context Therapeutics Inc. has selected CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin-6 (CLDN6)-positive cancers. Resulting from a ...
Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context Therapeutics presented a Trial in Progress poster for its Phase 1 clinical trial ...
PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE)-- Context Therapeutics Inc. ("Context” or the "Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results